
    
      Visit 1 screening will determine eligibility and obtain informed consent. At visit 2, 3 and 4
      subjects inhale 1 dose of 45U TI Inhalation Powder. At visit 3 subjects inhale 2 puffs
      (200mcg) Albuterol prior to dosing. Only asthmatic subjects undergo visit 4 where a
      methacholine challenge test (MCT) is performed followed by inhalation of Albuterol then
      administration of TI Inhalation Powder. Each visit's dosing will occur during a
      hyperinsulinemic euglycemic clamp. Visit 5 is the follow up visit.
    
  